Its price target of $320 suggests shares could rally 25% from Tuesday's close. "Amgen is a best-in-class operator with high margins and a strong history of protecting its assets. While some very old products are finally facing patent cliffs it will likely be gradual and a broadened portfolio allows for continued growth," analyst Morten Herholdt wrote in a Wednesday note.
mountain AMGN in 2023 — CNBC's Michael Bloom contributed to this report.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: